Skip to main content
. Author manuscript; available in PMC: 2016 Oct 21.
Published in final edited form as: Drug Target Rev. 2016 Jun 16;3(2):34–38.

Figure 3.

Figure 3

Summary of the many biomedical opportunities enabled by the iPSC technology (“patient in a dish”). For instance, after generating specific neuronal subtypes representative of various neurotransmitter systems (e.g. glutamatergic, GABAergic, dopaminergic), these cells can be investigated as pure and mixed cultures and subjected to various manipulations (e.g. polypharmacology) for new target identification (ID), predictive toxicology, and other purposes.